Researchers found that right after the third shot of the Pfizer vaccine, protection against a symptomatic infection is pretty good. Two weeks after the shot, the booster cuts the risk by about 70%.
"Pfizer-BioNTech"
Experts advising FDA vote against Pfizer COVID booster
Presentations generally showed the vaccine was still effective in protecting immunized people against severe illness, hospitalization and death in the U.S.
Pfizer-BioNTech’s COVID vaccine gets full approval from the FDA
The Food and Drug Administration has formally approved Pfizer’s COVID-19 vaccine. The widely anticipated decision replaces the emergency use authorization granted by the agency last December.